These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18519772)

  • 41. Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.
    Honndorf VS; Wiehr S; Rolle AM; Schmitt J; Kreft L; Quintanilla-Martinez L; Kohlhofer U; Reischl G; Maurer A; Boldt K; Schwarz M; Schmidt H; Pichler BJ
    Oncotarget; 2016 May; 7(19):28247-61. PubMed ID: 27070087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
    Su H; Bodenstein C; Dumont RA; Seimbille Y; Dubinett S; Phelps ME; Herschman H; Czernin J; Weber W
    Clin Cancer Res; 2006 Oct; 12(19):5659-67. PubMed ID: 17020967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
    Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
    Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
    Takano A; Usui I; Haruta T; Kawahara J; Uno T; Iwata M; Kobayashi M
    Mol Cell Biol; 2001 Aug; 21(15):5050-62. PubMed ID: 11438661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
    Tseng JC; Narayanan N; Ho G; Groves K; Delaney J; Bao B; Zhang J; Morin J; Kossodo S; Rajopadhye M; Peterson JD
    PLoS One; 2017; 12(8):e0182689. PubMed ID: 28792505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.
    De Giorgi U; Amadori D
    J Clin Oncol; 2010 May; 28(15):e236-7; author reply e238. PubMed ID: 20177016
    [No Abstract]   [Full Text] [Related]  

  • 49. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
    Leyton J; Smith G; Lees M; Perumal M; Nguyen QD; Aigbirhio FI; Golovko O; He Q; Workman P; Aboagye EO
    Mol Cancer Ther; 2008 Sep; 7(9):3112-21. PubMed ID: 18790789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
    Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
    J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Inhibition of 18F-FDG uptake in glioblastoma cells by FDG and glucose].
    Oehr P; Ruhlmann J; Kozak B; Brock H; Thieme D; Rink H
    Acta Med Austriaca; 1999; 26(3):101-3. PubMed ID: 10520378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mammalian target of rapamycin (mTOR) Inhibitors.
    Dutcher JP
    Curr Oncol Rep; 2004 Mar; 6(2):111-5. PubMed ID: 14751088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
    Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
    J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
    Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
    Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
    Xu RH; Pelicano H; Zhang H; Giles FJ; Keating MJ; Huang P
    Leukemia; 2005 Dec; 19(12):2153-8. PubMed ID: 16193082
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Jiang Y; Zeng Q; Jiang Q; Peng X; Gao J; Wan H; Wang L; Gao Y; Zhou X; Lin D; Feng H; Liang S; Zhou H; Ding J; Ai J; Huang R
    Theranostics; 2022; 12(14):6395-6408. PubMed ID: 36168616
    [No Abstract]   [Full Text] [Related]  

  • 60. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.
    Lee SC; Marzec M; Liu X; Wehrli S; Kantekure K; Ragunath PN; Nelson DS; Delikatny EJ; Glickson JD; Wasik MA
    NMR Biomed; 2013 Jan; 26(1):106-14. PubMed ID: 22711601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.